XNAS
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -3.18 | -4.68 | -47.17% | $-1.5M | ❌ Miss | -1.28% | +3.98% | — |
| 2026-05-11 | Q1 2026 | — | -3.74 | -11.90% | $3.7M | — | +0.74% | +0.44% | -1.62% |
| 2026-03-16 |
| Q4 2025 |
| -3.89 |
| -3.61 |
| +7.20% |
| $1.3M |
| ✅ Beat |
| +0.00% |
| +0.86% |
| +1.71% |
Showing last 3 quarters.